Celecoxib aggravates cardiac apoptosis in L-NAME-induced pressure overload model in rats: Immunohistochemical determination of cardiac caspase-3, Mcl-1, Bax and Bcl-2

Chemico-Biological Interactions

Volumn 272, Issue , 2017, Pages 92-106

  Mosaad, Sarah M ^a   Zaitone, Sawsan A ^b,c   Ibrahim, Abdelazim ^d,e   El Baz, Amani A ^d   Abo Elmatty, Dina M ^b   Moustafa, Yasser M ^b  

^a MINISTRY OF HEALTH   (Egypt)

^b Suez Canal University   (Egypt)

^c UNIVERSITY OF TABUK   (Saudi Arabia)

^d Suez Canal University   (Egypt)

^e KING FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Cardiac apoptosis; Celecoxib; Fibrosis; L NAME; Myocardial hypertrophy; Rat

Indexed keywords

CASPASE 3; CELECOXIB; CREATINE KINASE MB; LACTATE DEHYDROGENASE; NITRATE; NITRIC OXIDE; NITRITE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; MCL1 PROTEIN, RAT; N(G) NITROARGININE METHYL ESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIAC MUSCLE CELL; CARDIOTOXICITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DNA FRAGMENTATION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MORTALITY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; WISTAR RAT; ANIMAL; BLOOD; BLOOD PRESSURE; CARDIAC MUSCLE; CARDIOMEGALY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; RAT;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOOD PRESSURE; CARDIOMEGALY; CASPASE 3; CELECOXIB; CREATINE KINASE, MB FORM; DISEASE MODELS, ANIMAL; DNA FRAGMENTATION; L-LACTATE DEHYDROGENASE; MALE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, WISTAR;

EID: 85019907947     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2017.05.012     Document Type: Article

References (82)

1. Moodley, I., Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc. J. Afr. 19 (2008), 102–107.
2. Simon, L.S., Weaver, A.L., Graham, D.Y., Kivitz, A.J., Lipsky, P.E., Hubbard, R.C., Isakson, P.C., Verburg, K.M., Yu, S.S., Zhao, W.W., Geis, G.S., Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 282 (1999), 1921–1928.
3. Williams, C.S., Watson, A.J., Sheng, H., Helou, R., Shao, J., DuBois, R.N., Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60 (2000), 6045–6051.
4. Zweifel, B.S., Davis, T.W., Ornberg, R.L., Masferrer, J.L., Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res. 62 (2002), 6706–6711.
5. Trifan, O.C., Durham, W.F., Salazar, V.S., Horton, J., Levine, B.D., Zweifel, B.S., Davis, T.W., Masferrer, J.L., Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 62 (2002), 5778–5784.
6. FitzGerald, G.A., COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2 (2003), 879–890, 10.1038/nrd1225.
7. Zaitone, S.A., Moustafa, Y.M., Mosaad, S.M., El-Orabi, N.F., Effect of evening primrose oil and ω-3 polyunsaturated fatty acids on the cardiovascular risk of celecoxib in rats. J. Cardiovasc. Pharmacol. 58 (2011), 72–79, 10.1097/FJC.0b013e31821c8353.
8. Catella-Lawson, F., Reilly, M.P., Kapoor, S.C., Cucchiara, A.J., DeMarco, S., Tournier, B., Vyas, S.N., FitzGerald, G.A., Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345 (2001), 1809–1817, 10.1056/NEJMoa003199.
9. Catella-Lawson, F., McAdam, B., Morrison, B.W., Kapoor, S., Kujubu, D., Antes, L., Lasseter, K.C., Quan, H., Gertz, B.J., FitzGerald, G.A., Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289 (1999), 735–741.
10. Rabausch, K., Bretschneider, E., Sarbia, M., Meyer-Kirchrath, J., Censarek, P., Pape, R., Fischer, J.W., Schrör, K., Weber, A.-A., Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ. Res. 96 (2005), e1–6, 10.1161/01.RES.0000153150.27690.f2.
11. Saini, S.S., Gessell-Lee, D.L., Peterson, J.W., The cox-2-specific inhibitor celecoxib inhibits adenylyl cyclase. Inflammation 27 (2003), 79–88.
12. Ghosh, M., Wang, H., Ai, Y., Romeo, E., Luyendyk, J.P., Peters, J.M., Mackman, N., Dey, S.K., Hla, T., COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J. Exp. Med. 204 (2007), 2053–2061, 10.1084/jem.20070828.
13. Klinge, J.M., Topf, H.-G., Trusen, B., Rauh, M., Rascher, W., Dötsch, J., Endothelial cells play an important role in the antiaggregatory effect of nitric oxide. Crit. Care Med. 31 (2003), 2010–2014, 10.1097/01.CCM.0000069339.42383.16.
14. Arnal, J.F., Warin, L., Michel, J.B., Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J. Clin. Invest 90 (1992), 647–652, 10.1172/JCI115906.
15. Baylis, C., Mitruka, B., Deng, A., Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J. Clin. Invest 90 (1992), 278–281, 10.1172/JCI115849.
16. Simko, F., Matuskova, J., Luptak, I., Krajcirovicova, K., Kucharska, J., Gvozdjakova, A., Babal, P., Pechanova, O., Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci. 74 (2004), 1211–1224.
17. Liu, P., Xu, B., Forman, L.J., Carsia, R., Hock, C.E., L-NAME enhances microcirculatory congestion and cardiomyocyte apoptosis during myocardial ischemia-reperfusion in rats. Shock Augusta Ga 17 (2002), 185–192.
18. Weller, R., Schwentker, A., Billiar, T.R., Vodovotz, Y., Autologous nitric oxide protects mouse and human keratinocytes from ultraviolet B radiation-induced apoptosis. Am. J. Physiol. Cell Physiol. 284 (2003), C1140–C1148, 10.1152/ajpcell.00462.2002.
19. Mital, S., Barbone, A., Addonizio, L.J., Quaegebeur, J.M., Mosca, R.J., Oz, M.C., Hintze, T.H., Endogenous endothelium-derived nitric oxide inhibits myocardial caspase activity: implications for treatment of end-stage heart failure. J. Heart Lung Transpl. Off. Publ. Int. Soc. Heart Transpl. 21 (2002), 576–585.
20. Lv, L., Jiang, S.-S., Xu, J., Gong, J.-B., Cheng, Y., Protective effect of ligustrazine against myocardial ischaemia reperfusion in rats: the role of endothelial nitric oxide synthase. Clin. Exp. Pharmacol. Physiol. 39 (2012), 20–27, 10.1111/j.1440-1681.2011.05628.x.
21. Hengartner, M.O., Horvitz, H.R., Programmed cell death in Caenorhabditis elegans. Curr. Opin. Genet. Dev. 4 (1994), 581–586.
22. Liang, Q., Molkentin, J.D., Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J. Mol. Cell. Cardiol. 35 (2003), 1385–1394.
23. Jendrossek, V., Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett. 332 (2013), 313–324, 10.1016/j.canlet.2011.01.012.
24. Ribeiro, M.O., Antunes, E., de Nucci, G., Lovisolo, S.M., Zatz, R., Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20 (1992), 298–303.
25. Jover, B., Herizi, A., Ventre, F., Dupont, M., Mimran, A., Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension 21 (1993), 944–948.
26. Rhaleb, N.E., Yang, X.P., Scicli, A.G., Carretero, O.A., Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension 23 (1994), 865–868.
27. Babál, P., Pechánová, O., Bernátová, I., Stvrtina, S., Chronic inhibition of NO synthesis produces myocardial fibrosis and arterial media hyperplasia. Histol. Histopathol. 12 (1997), 623–629.
28. Chillon, J.M., Ghoneim, S., Baumbach, G.L., Effects of chronic nitric oxide synthase inhibition on cerebral arterioles in rats. Hypertension 30 (1997), 1097–1104.
29. Moreau, P., Takase, H., d'Uscio, L.V., Lüscher, T.F., Effect of chronic nitric oxide deficiency on angiotensin II-induced hypertrophy of rat basilar artery. Stroke J. Cereb. Circ. 29 (1998), 1031–1035 1036.
30. Numaguchi, K., Egashira, K., Takemoto, M., Kadokami, T., Shimokawa, H., Sueishi, K., Takeshita, A., Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 26 (1995), 957–962.
31. Moreno, H., Metze, K., Bento, A.C., Antunes, E., Zatz, R., de Nucci, G., Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic Res. Cardiol. 91 (1996), 248–255.
32. Radomski, M.W., Palmer, R.M., Moncada, S., Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet lond. Engl. 2 (1987), 1057–1058.
33. Vanhoutte, P.M., Shimokawa, H., Endothelium-derived relaxing factor and coronary vasospasm. Circulation 80 (1989), 1–9.
34. Ikeda, H., Tsuruya, K., Toyonaga, J., Masutani, K., Hayashida, H., Hirakata, H., Iida, M., Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. Kidney Int. 75 (2009), 147–155, 10.1038/ki.2008.507.
35. Koçkaya, E.A., Selmanoğlu, G., Kismet, K., Akay, M.T., Pathological and biochemical effects of therapeutic and supratherapeutic doses of celecoxib in Wistar albino male rats. Drug Chem. Toxicol. 33 (2010), 410–414, 10.3109/01480540903575691.
36. Cheng, Y., Wang, M., Yu, Y., Lawson, J., Funk, C.D., Fitzgerald, G.A., Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest 116 (2006), 1391–1399, 10.1172/JCI27540.
37. Francois, H., Makhanova, N., Ruiz, P., Ellison, J., Mao, L., Rockman, H.A., Coffman, T.M., A role for the thromboxane receptor in L-NAME hypertension. Am. J. Physiol. Ren. Physiol. 295 (2008), F1096–F1102, 10.1152/ajprenal.00369.2007.
38. Zanfolin, M., Faro, R., Araujo, E.G., Guaraldo, A.M.A., Antunes, E., De Nucci, G., Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J. Cardiovasc. Pharmacol. 47 (2006), 391–395 fjc.0000210071.54828.9b.
39. Green, L.C., Wagner, D.A., Glogowski, J., Skipper, P.L., Wishnok, J.S., Tannenbaum, S.R., Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 126 (1982), 131–138.
40. Zaitone, S.A., Abo-Gresha, N.M., Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: role of iNOS and VEGF. Eur. J. Pharmacol. 691 (2012), 134–142, 10.1016/j.ejphar.2012.06.022.
41. Ali, S.A., Zaitone, S.A., Moustafa, Y.M., Boswellic acids synergize antitumor activity and protect against the cardiotoxicity of doxorubicin in mice bearing Ehrlich's carcinoma. Can. J. Physiol. Pharmacol. 93 (2015), 695–708, 10.1139/cjpp-2014-0524.
42. Ruifrok, A.C., Johnston, D.A., Quantification of histochemical staining by color deconvolution. Anal. Quant. Cytol. Histol. Int. Acad. Cytol. Am. Soc. Cytol. 23 (2001), 291–299.
43. Radovits, T., Korkmaz, S., Mátyás, C., Oláh, A., Németh, B.T., Páli, S., Hirschberg, K., Zubarevich, A., Gwanmesia, P.N., Li, S., Loganathan, S., Barnucz, E., Merkely, B., Szabó, G., An altered pattern of myocardial histopathological and molecular changes underlies the different characteristics of Type-1 and Type-2 diabetic cardiac dysfunction. J. Diabetes Res. 2015 (2015), 1–12, 10.1155/2015/728741.
44. McAdams, R.M., McPherson, R.J., Dabestani, N.M., Gleason, C.A., Juul, S.E., Left ventricular hypertrophy is prevalent in Sprague-Dawley rats. Comp. Med. 60 (2010), 357–363.
45. Papanicolaou, K.N., Streicher, J.M., Ishikawa, T.-O., Herschman, H., Wang, Y., Walsh, K., Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2. J. Mol. Cell. Cardiol. 49 (2010), 196–209, 10.1016/j.yjmcc.2010.04.002.
46. Arends, M.J., Wyllie, A.H., Apoptosis: mechanisms and roles in pathology. Int. Rev. Exp. Pathol. 32 (1991), 223–254.
47. Gown, A.M., Willingham, M.C., Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J. Histochem. Cytochem. Off. J. Histochem. Soc. 50 (2002), 449–454.
48. Zidar, N., Dolenc-Strazar, Z., Jeruc, J., Stajer, D., Immunohistochemical expression of activated caspase-3 in human myocardial infarction. Virchows Arch. Int. J. Pathol. 448 (2006), 75–79, 10.1007/s00428-005-0073-5.
49. Stasch, J.P., Becker, E.M., Alonso-Alija, C., Apeler, H., Dembowsky, K., Feurer, A., Gerzer, R., Minuth, T., Perzborn, E., Pleiss, U., Schröder, H., Schroeder, W., Stahl, E., Steinke, W., Straub, A., Schramm, M., NO-independent regulatory site on soluble guanylate cyclase. Nature 410 (2001), 212–215, 10.1038/35065611.
50. Devlin, A.M., Brosnan, M.J., Graham, D., Morton, J.J., McPhaden, A.R., McIntyre, M., Hamilton, C.A., Reid, J.L., Dominiczak, A.F., Vascular smooth muscle cell polyploidy and cardiomyocyte hypertrophy due to chronic NOS inhibition in vivo. Am. J. Physiol. 274 (1998), H52–H59.
51. Pacca, S.R.M.C., de Azevedo, A.P., De Oliveira, C.F., De Luca, I.M.S., De Nucci, G., Antunes, E., Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 39 (2002), 201–207.
52. Moreno, H., Piovesan Nathan, L., Pereira Costa, S.K., Metze, K., Antunes, E., Zatz, R., De Nucci, G., Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide synthesis. Eur. J. Pharmacol. 287 (1995), 93–96.
53. Kumar, S., Prahalathan, P., Raja, B., Vanillic acid: a potential inhibitor of cardiac and aortic wall remodeling in l-NAME induced hypertension through upregulation of endothelial nitric oxide synthase. Environ. Toxicol. Pharmacol. 38 (2014), 643–652, 10.1016/j.etap.2014.07.011.
54. Kitamoto, S., Egashira, K., Kataoka, C., Usui, M., Koyanagi, M., Takemoto, M., Takeshita, A., Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J. Hypertens. 18 (2000), 1795–1800.
55. McNamara, D.B., Bedi, B., Aurora, H., Tena, L., Ignarro, L.J., Kadowitz, P.J., Akers, D.L., L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem. Biophys. Res. Commun. 193 (1993), 291–296, 10.1006/bbrc.1993.1622.
56. Pechánová, O., Bernátová, I., Pelouch, V., Babál, P., L-NAME-induced protein remodeling and fibrosis in the rat heart. Physiol. Res. Acad. Sci. Bohemoslov. 48 (1999), 353–362.
57. Rossi, M.A., Ramos, S.G., Prado, C.M., Chronic inhibition of nitric oxide synthase induces hypertension and cardiomyocyte mitochondrial and myocardial collagen remodelling in the absence of hypertrophy. J. Hypertens. 21 (2003), 993–1001, 10.1097/01.hjh.0000059019.82022.2e.
58. Cheng, W., Li, B., Kajstura, J., Li, P., Wolin, M.S., Sonnenblick, E.H., Hintze, T.H., Olivetti, G., Anversa, P., Stretch-induced programmed myocyte cell death. J. Clin. Invest 96 (1995), 2247–2259, 10.1172/JCI118280.
59. Leri, A., Claudio, P.P., Li, Q., Wang, X., Reiss, K., Wang, S., Malhotra, A., Kajstura, J., Anversa, P., Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J. Clin. Invest 101 (1998), 1326–1342, 10.1172/JCI316.
60. Smith, R.S., Agata, J., Xia, C.-F., Chao, L., Chao, J., Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci. 76 (2005), 2457–2471, 10.1016/j.lfs.2004.11.028.
61. Akashiba, A., Ono, H., Ono, Y., Ishimitsu, T., Matsuoka, H., Valsartan improves l-NAME-exacerbated cardiac fibrosis with TGF-β inhibition and apoptosis induction in spontaneously hypertensive rats. J. Cardiol. 52 (2008), 239–246, 10.1016/j.jjcc.2008.07.018.
62. Ono, Y., Ono, H., Matsuoka, H., Fujimori, T., Frohlich, E.D., Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertension 34 (1999), 609–616.
63. Anning, P.B., Coles, B., Morton, J., Wang, H., Uddin, J., Morrow, J.D., Dey, S.K., Marnett, L.J., O'Donnell, V.B., Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood 108 (2006), 4059–4062, 10.1182/blood-2006-02-005330.
64. Shishodia, S., Aggarwal, B.B., Nuclear factor-kappaB activation: a question of life or death. J. Biochem. Mol. Biol. 35 (2002), 28–40.
65. Yu, Y., Ricciotti, E., Scalia, R., Tang, S.Y., Grant, G., Yu, Z., Landesberg, G., Crichton, I., Wu, W., Puré, E., Funk, C.D., FitzGerald, G.A., Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci. Transl. Med., 4, 2012, 132ra54, 10.1126/scitranslmed.3003787.
66. Yuan, J., Molecular control of life and death. Curr. Opin. Cell Biol. 7 (1995), 211–214.
67. Komatsu, K., Buchanan, F., Katkuri, S., Morrow, J., Inoue, H., Otaka, M., Watanabe, S., Dubois, R., Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via Cyclooxygenase-2. Gastroenterology 129 (2005), 577–590, 10.1016/j.gastro.2005.06.003.
68. Lin, M.-T., Lee, R.-C., Yang, P.-C., Ho, F.-M., Kuo, M.-L., Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells: INVOLVEMENT of phosphatidylinositol 3-kinase/akt pathway. J. Biol. Chem. 276 (2001), 48997–49002, 10.1074/jbc.M107829200.
69. Rudner, J., Elsaesser, S.J., Müller, A.-C., Belka, C., Jendrossek, V., Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis. Biochem. Pharmacol. 79 (2010), 10–20, 10.1016/j.bcp.2009.07.021.
70. Robich, M.P., Chu, L.M., Feng, J., Burgess, T.A., Laham, R.J., Bianchi, C., Sellke, F.W., Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium. J. Thorac. Cardiovasc. Surg. 140 (2010), 1143–1152, 10.1016/j.jtcvs.2010.06.057.
71. Zhang, C., Wang, F., Zhang, Y., Kang, Y., Wang, H., Si, M., Su, L., Xin, X., Xue, F., Hao, F., Yu, L., Xu, J., Liu, Y., Xue, M., Celecoxib prevents pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress. J. Cell. Mol. Med. 20 (2016), 116–127, 10.1111/jcmm.12709.
72. Teiger, E., Than, V.D., Richard, L., Wisnewsky, C., Tea, B.S., Gaboury, L., Tremblay, J., Schwartz, K., Hamet, P., Apoptosis in pressure overload-induced heart hypertrophy in the rat. J. Clin. Invest 97 (1996), 2891–2897, 10.1172/JCI118747.
73. Olivetti, G., Abbi, R., Quaini, F., Kajstura, J., Cheng, W., Nitahara, J.A., Quaini, E., Di Loreto, C., Beltrami, C.A., Krajewski, S., Reed, J.C., Anversa, P., Apoptosis in the failing human heart. N. Engl. J. Med. 336 (1997), 1131–1141, 10.1056/NEJM199704173361603.
74. Condorelli, G., Morisco, C., Stassi, G., Notte, A., Farina, F., Sgaramella, G., de Rienzo, A., Roncarati, R., Trimarco, B., Lembo, G., Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation 99 (1999), 3071–3078.
75. Niederberger, E., Manderscheid, C., Grösch, S., Schmidt, H., Ehnert, C., Geisslinger, G., Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem. Pharmacol. 68 (2004), 341–350, 10.1016/j.bcp.2004.03.029.
76. Jendrossek, V., Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett. 332 (2013), 313–324, 10.1016/j.canlet.2011.01.012.
77. Lev-Ari, S., Zinger, H., Kazanov, D., Yona, D., Ben-Yosef, R., Starr, A., Figer, A., Arber, N., Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed. Pharmacother. Bioméd. Pharmacothérapie 59:Suppl 2 (2005), S276–S280.
78. Subhashini, J., Mahipal, S.V.K., Reddanna, P., Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett. 224 (2005), 31–43, 10.1016/j.canlet.2004.11.002.
79. Olivetti, G., Melissari, M., Balbi, T., Quaini, F., Cigola, E., Sonnenblick, E.H., Anversa, P., Myocyte cellular hypertrophy is responsible for ventricular remodelling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc. Res. 28 (1994), 1199–1208.
80. Bing, O.H., Ngo, H.Q., Humphries, D.E., Robinson, K.G., Lucey, E.C., Carver, W., Brooks, W.W., Conrad, C.H., Hayes, J.A., Goldstein, R.H., Localization of alpha1(I) collagen mRNA in myocardium from the spontaneously hypertensive rat during the transition from compensated hypertrophy to failure. J. Mol. Cell. Cardiol. 29 (1997), 2335–2344, 10.1006/jmcc.1997.0465.
81. Fortuño, M.A., Ravassa, S., Fortuño, A., Zalba, G., Díez, J., Cardiomyocyte apoptotic cell death in arterial hypertension: mechanisms and potential management. Hypertension 38 (2001), 1406–1412.
82. Howes, L.G., Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?. Ther. Clin. Risk Manag. 3 (2007), 831–845.